Differential Healing After Sirolimus, Paclitaxel and Bare Metal Stent Placement in Combination with PPARγ Agonists: Requirement for mTOR/Akt2 in PPARγ Activation

RATIONALE: Sirolimus- (SES) and paclitaxel-eluting coronary stents (PES) are used to reduce restenosis, but have different sites of action. The molecular targets of sirolimus (SRL) overlap with those of the PPARγ agonist, rosiglitazone (RSG), but the consequence of this interaction on endothelializa...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Circ Res
Asıl Yazarlar: Finn, Aloke V., John, Michael, Nakazawa, Gaku, Polavarapu, Rohini, Karmali, Vinit, Xu, Xin, Cheng, Qi, Davis, Talina, Raghunathan, Chitra, Acampado, Eduardo, Ezell, Tucker, Lajoie, Scott, Eppihimer, Michael, Kolodgie, Frank D., Virmani, Renu, Gold, Herman Kalman
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2009
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4492118/
https://ncbi.nlm.nih.gov/pubmed/19797172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCRESAHA.109.200519
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller